Who founded Normunity?

Normunity was founded by Rachel Humphrey, Lieping Chen.

Who are Normunity's investors?

Normunity's investors include Sanofi Ventures, Taiho Ventures, LLC, Pfizer Ventures, Samsara BioCapital, Canaan Partners, Connecticut Innovations, Pfizer Venture Investments, HongShan Capital Group and 2 more.

Normunity

12 known investors

normunity.com ↗

Normunity is a cancer immunotherapy company applying an immunology-based approach to identify novel anti-cancer targets at the interface of the immune system and cancer, using proprietary platforms and human cells and tissues. Founded in partnership with the lab of Dr. Lieping Chen at Yale School of Medicine, it is developing a pipeline of oncology therapies targeting proteins that help tumors evade immune surveillance.

AI & Machine LearningBiotechHealthtech

Founders & leadership

Rachel HumphreyFounding Chief Executive Officer

Lieping ChenScientific Founder

Mitchell KeeganChief Development Officer

William LaRochelleChief Scientific Officer

Stacy M. PlumChief Technology Officer

Investors · 12

Sanofi Ventures✓ verifiedCambridge · $5M

Taiho Ventures, LLC✓ verifiedMenlo Park

Pfizer Ventures✓ verified

Samsara BioCapital✓ verifiedPalo Alto

Canaan PartnersStamford · $500K – $20M

Connecticut InnovationsNew Haven · $500K – $2M

Pfizer Venture Investments$5M – $20M

HongShan Capital GroupreportedHong Kong · $100K – $50M

Osage Venture PartnersreportedBala Cynwyd · $500K – $3M

YK Bioventuresreported · 2 sourcesBurlingame

Also in the syndicate · 2

Enavate SciencesleadRegeneron Ventures

Funding

SEC filings, press & company announcements

Undisclosed amountSeries BJan 2025
Enavate Sciences (lead), Samsara BioCapital (lead), Canaan Partners, Connecticut Innovations, HongShan Capital Group, Osage Venture Partners, Pfizer Ventures, Regeneron Ventures, Sanofi Ventures, Taiho Ventures, YK Bioventures
Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

Competitors · 1

by search overlap

Immunome10 shared keywordsImmunome is a clinical-stage oncology company developing targeted cancer therapies, including antibody-drug conjugates (ADCs) and small molecules, to address unmet medical needs in cancers such as lymphoma and bladder cancer. It also acquires targeted oncology assets and advances them through manufacturing and clinical development.

Companies competing with Normunity for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Normunity raises $75m to advance solid tumour targeting T-cell engagers - Pharmaceutical Technologypharmaceutical-technology.com · Jan 2025

Normunity: $75 Million (Series B) Raised For Broadening Pipeline Of Novel Anti-Cancer Therapiespulse2.com · Jan 2025

Normunity Closes $75 Million Series B Financing to Advance Lead Drug Program Into the Clinic and Broaden Pipeline of Novel Anti-Cancer Therapies Targeting Untapped Drug Mechanismsbusinesswire.com · Jan 2025

Normunity Raises $65M in Series A Financingfinsmes.com · Oct 2022

About Us - Normunitynormunity.com · Aug 2022

Frequently asked questions

What does Normunity do?: Normunity is a cancer immunotherapy company applying an immunology-based approach to identify novel anti-cancer targets at the interface of the immune system and cancer, using proprietary platforms and human cells and tissues. Founded in partnership with the lab of Dr. Lieping Chen at Yale School of Medicine, it is developing a pipeline of oncology therapies targeting proteins that help tumors evade immune surveillance.
Who founded Normunity?: Normunity was founded by Rachel Humphrey, Lieping Chen.
Who are Normunity's investors?: Normunity's investors include Sanofi Ventures, Taiho Ventures, LLC, Pfizer Ventures, Samsara BioCapital, Canaan Partners, Connecticut Innovations, Pfizer Venture Investments, HongShan Capital Group and 2 more.